Cell Therapeutics (CTIC Quote) jumped by 21 cents, or 18%, to $1.38 on reports the Food and Drug Administration's Oncologic Drugs Advisory Committee would review the company's new drug application for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma on Feb. 10 . Volume topped 24.65 million shares, compared to the 50-day average daily volume of 9.87 million.